Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

Authors

Christophe Le Tourneau

Institut Curie, Saint-Cloud, France

Christophe Le Tourneau , Valentin Calugaru , Zoltan Takacsi-Nagy , Xavier Liem , Zsuzsanna Papai , Jacek Fijuth , Victor Moreno , Jordi Giralt , Sébastien Salas , Gilles Poissonnet , Emiliano Calvo , Bernard Doger , Olivier Choussy , Xavier Mirabel , Samar Krhili , Katell Bernois , Nicolas Fakhry , Stéphanie Wong-Hee-Kam , Edith Borcoman , Caroline Hoffmann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT01946867

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6051)

DOI

10.1200/JCO.2021.39.15_suppl.6051

Abstract #

6051

Poster Bd #

Online Only

Abstract Disclosures

FEATURED

Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

Authors

Christophe Le Tourneau

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Poster

A phase 1 trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC).

Poster

NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.

Poster

Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma.